Clinical trials: Flushing
Flushing
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone. Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood…
- Trial name
- NCT00536237
- Testing
- Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Hot Flashes
Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.
- Trial name
- NCT00511953
- Testing
- Gabapentin Extended Release tablets, Gabapentin
- Where
- 8 sites in United States
- Volunteers
- 108 people
- Sponsor
- Depomed
Vasomotor System
ZK283197 for Treatment of Vasomotor Symptoms
The primary goal of the planned study is to investigate the efficacy and safety of ZK 283197 in the dosage of 2 and 3 mg ingested once daily during a period of 8 weeks for the treatment of hot flushes.
- Trial name
- NCT00537836
- Testing
- BAY 86-5310 (ZK 283197), 17ß-estradiol
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- Bayer
Flushing
Endpoint Validation Study (0524A-015)
To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).
- Trial name
- NCT00533676
- Testing
- MK0524A, /Duration of Treatment : 8 Weeks
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Sensitive Skin
Instant Flush Redness Clinical Efficacy Study
The goal of this clinical trial is to learn if an anti-redness emulsion can help lower facial redness caused by heat in healthy adult women.
- Trial name
- NCT07067476
- Testing
- Instant Anti-Redness Emulsion (FLA#2039188 43), Purified Water (Control)
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ChinaNorm
Urinary Tract
Evaluating the Efficacy of the Flush Advanced+ Dietary Supplement Drink Mix Compared to a Placebo in Women Ages 18-75 With a History of Recurrent, Bothersome Urinary Tract Symptoms
The goal of this clinical trial is to evaluate the efficacy of the Flush Advanced+ dietary drink mix to reduce bothersome urinary tract symptoms compared to a placebo.
- Trial name
- NCT07856550
- Testing
- Flush Advanced+ Dietary Drink Mix
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Bonafide Health
Healthy Subjects, Dyslipidaemias
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
- Trial name
- NCT00608699
- Testing
- GSK256073A tablets + IR niacin tablets
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infertility
A Phase II Clinical Study of Lidocain Pertubation as Treatment for Couples With Unexplained Infertility
The study tested the hypothesis that a pertubation with a lidocain solution will enhance pregnancy rate.
- Trial name
- NCT00449449
- Testing
- Pertubation with Lidocain Solution
- Where
- Sweden
- Volunteers
- 330 people
- Sponsor
- Isifer AB
Carcinoid Syndrome
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c.
- Trial name
- ELECT (NCT00774930)
- Testing
- Lanreotide
- Where
- 54 sites in United States, Brazil and 9 more
- Volunteers
- 115 people
- Sponsor
- Ipsen
Relapsing-Remitting Multiple Sclerosis
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of the study is to evaluate whether 150 mg enteric-coated aspirin (acetylsalicylic acid [ASA]) taken twice a day (BID) with dimethyl fumarate (DMF) administration or 75 mg enteric-coated ASA taken once daily…
- Trial name
- ASSURE (NCT02090413)
- Testing
- dimethyl fumarate, acetylsalicylic acid
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 241 people
- Sponsor
- Biogen
Postmenopause
Endometrial Safety Study
The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).
- Trial name
- NCT00522873
- Testing
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 662 people
- Sponsor
- Bayer
Cancer
Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters
This study is to compare the rate of adverse events in subjects with maintenance flushes greater than 28 days.
- Trial name
- DISTAL (NCT01586026)
- Where
- 5 sites in United States
- Volunteers
- 171 people
- Sponsor
- C. R. Bard
Rosacea
Effect of CD07805/47 Gel in Rosacea Flushing
Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.
- Trial name
- NCT02300129
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). The symptoms of VMS are hot flashes. These symptoms can be caused by changes in sex hormone levels.
- Trial name
- NCT05071729
- Testing
- Elinzanetant (BAY3427080)
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Bayer
Dyslipidemia
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.
- Trial name
- NCT00111891
- Testing
- niacin (+) laropiprant
- Volunteers
- 575 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hot Flashes
Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Depomed's Gabapentin Extended Release (G-ER) is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.
- Trial name
- NCT00755417
- Testing
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg
- Where
- 45 sites in United States
- Volunteers
- 541 people
- Sponsor
- Depomed
Hot Flashes
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.
- Trial name
- NCT00314964
- Testing
- PD-0299685
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 527 people
- Sponsor
- Pfizer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). VMS such as hot flashes are caused by hormonal changes occurring during menopausal transition when women may have also changes in their…
- Trial name
- NCT05061563
- Testing
- Elinzanetant (BAY3427080), Esomeprazole
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Flushing
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
- Trial name
- NCT00533611
- Testing
- MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Hot Flashes
A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.
- Trial name
- NCT00875420
- Testing
- RAD1901
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Radius Pharmaceuticals, Inc.